ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots
ACC 2025: Lower-Dose Apixaban Is Effective, Safer Than Full Dose for Preventing VTE Recurrence in Patients With Cancer
ACC 2025: Semaglutide Significantly Improves Walking Distance, Symptoms, QOL for Individuals with PAD and Diabetes
NCCN 2025: Immune Checkpoint Inhibitors Expand Treatment Options for Early-Stage NSCLC